Key result
Oncologic agents, including classical and immunological therapies, produce a variety of cardiovascular adverse effects such as cardiomyopathy, heart failure, and coronary artery disease.
Why the study?
What are the cardiovascular adverse effects of classical and large molecule immunological anti-cancer agents in patients with cancer?
Population
Patients with cancer exposed to cancer therapy
Design
Review
Authors
Loading...
Alerts clinicians to cardiotoxicity risks in aging cancer survivors; leaves open optimal monitoring and prevention strategies.
What are the cardiovascular adverse effects of classical and large molecule immunological anti-cancer agents in patients with cancer?
This review highlights the diverse cardiovascular toxicities of anti-cancer therapies, emphasizing the need for cardio-oncology collaboration to manage these adverse effects.
Manolis et al. (2018) conducted a review in Cancer and cardiovascular disease. Anti-cancer drugs was evaluated on Cardiovascular and cardiometabolic toxicity. Oncologic agents, including classical and immunological therapies, produce a variety of cardiovascular adverse effects such as cardiomyopathy, heart failure, and coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: